Teleflex (NYSE:TFX – Get Free Report) and Elutia (NASDAQ:ELUT – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Profitability
This table compares Teleflex and Elutia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Teleflex | 13.51% | 10.57% | 4.96% |
| Elutia | 546.70% | -140.53% | -54.54% |
Valuation and Earnings
This table compares Teleflex and Elutia”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Teleflex | $2.26 billion | 2.92 | -$905.64 million | $8.23 | 20.18 |
| Elutia | $12.29 million | 2.99 | $53.38 million | $1.11 | 0.75 |
Elutia has lower revenue, but higher earnings than Teleflex. Elutia is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Teleflex has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Teleflex and Elutia, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Teleflex | 0 | 6 | 5 | 1 | 2.58 |
| Elutia | 1 | 0 | 0 | 0 | 1.00 |
Teleflex currently has a consensus price target of $163.30, suggesting a potential downside of 1.68%. Given Teleflex’s stronger consensus rating and higher probable upside, analysts clearly believe Teleflex is more favorable than Elutia.
Insider and Institutional Ownership
95.6% of Teleflex shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Teleflex beats Elutia on 9 of the 14 factors compared between the two stocks.
About Teleflex
Teleflex is a global medical technology company that develops, manufactures and markets single-use medical devices used by healthcare professionals in hospitals and other care settings. Its products support a range of procedures, including vascular access, anesthesia, critical care, surgery, urology and emergency medicine. The company’s offerings include vascular and interventional access devices, catheters, airway management products, surgical instruments and other devices used in diagnostic and therapeutic procedures.
About Elutia
Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
